# NCT04956640 (NCT04956640)

> Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04956640
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Eli Lilly and Company
- Conditions: Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Biliary Tract Neoplasms
- Interventions: LY3537982; Pembrolizumab; Cetuximab; Pemetrexed; Cisplatin; Carboplatin
- Enrollment: 540
- Primary outcome: Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy
- Primary outcome: Phase 1b: To assess the safety and tolerability of LY3537982 when administered alone or in combination with other investigational agents
- Primary outcome: Phase 1b: To determine the optimal dose of LY3537982 to be administered to treatment-naïve participants with advanced NSCLC in combination with pembrolizumab
- Primary outcome: To determine the optimal dose of LY3537982 to be administered to participants who have received at least one prior oxaliplatin- or irinotecan-containing regimen for advanced or metastatic CRC in combination with cetuximab
- Primary outcome: To assess the antitumor activity of LY3537982 monotherapy in participants with advanced pancreatic cancer with KRAS G12C mutation

## Commentary we found

- X threads: 7

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04956640